GlassScriptPhysician profile
Blake Thompson
NPI 1134624687
$7,638.64
in general payments reported to CMS, 2019-2025
29 companies · $3,720 in 2025
The $3,720 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $324 · 2023: $1,644 · 2024: $1,734 · 2025: $3,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,354 · Travel and Lodging: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,354.27 |
| Travel and Lodging | $742.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,320.24 | 2022-2025 | Mavyret, Skyrizi, Rinvoq |
| Boston Scientific Corporation | $1,617.75 | 2023-2025 | General - Therapies, General - Biliary Devices, Radial Jaw 4 |
| Madrigal Pharmaceuticals | $500.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $374.24 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.84 | 2021-2025 | Xifaxan, Relistor, Trulance |
| E.R. Squibb & Sons, L.L.C. | $304.21 | 2021-2024 | Zeposia |
| Medtronic, INC. | $301.88 | 2023-2024 | Endoflip, Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $240.46 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $211.13 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Ardelyx, INC. | $188.42 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $170.94 | 2022-2025 | Dupixent |
| Genzyme Corporation | $161.13 | 2024-2025 | |
| Sirtex Medical INC | $139.83 | 2023 | Sir-Spheres Microspheres |
| Olympus America INC. | $139.17 | 2024 | Visiglide |
| Aimmune Therapeutics, INC. | $119.52 | 2024-2025 | Zenpep |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Phathom Pharmaceuticals, INC. | $71.11 | 2024-2025 | Voquezna |
| Pfizer INC. | $49.65 | 2025 | |
| Enterra Medical, INC. | $49.20 | 2024-2025 | |
| Celgene Corporation | $48.13 | 2024 | Zeposia |
| Celltrion USA INC. | $34.95 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $32.94 | 2024 | Sutab |
| Ipsen Biopharmaceuticals, INC | $31.48 | 2025 | Iqirvo |
| Novo Nordisk INC | $26.78 | 2025 | Wegovy |
| Gilead Sciences, INC. | $20.56 | 2025 | |
| Vivus LLC | $20.09 | 2024 | Qsymia |
| Ironwood Pharmaceuticals, INC | $17.02 | 2024 | |
| Intercept Pharmaceuticals, INC. | $16.49 | 2024 | |
| Organon LLC | $16.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.